Bantam has raised approximately $20 million from private investors. The company and its current investors are seeking to syndicate a Series B round to:

1) Complete its cGMP manufacturing batch and production of clinical trial materials
2) Progress current lead program through IND-enabling studies and Phase 1a/1b clinical studies
3) Establish our unique Mechanism of Action as the foundation for a novel drug discovery platform

The above activities offer multiple near-term catalysts, including bringing the company to an exit via partnering event (licensing or acquisition by a Pharma/Biotech company) with a significant investor ROI.